全球顯影劑市場：策略分析與未來預測

Abstract

This report analyzes the worldwide markets for Imaging Agents in Millions of US$. The major product segments analyzed are Contrast Media (X-Ray, MRI, & Ultrasound), and Diagnostic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 67 companies including many key and niche players worldwide such as AMAG Pharmaceuticals Inc., Amersham Plc, Bayer Schering Pharma AG, Bayer HealthCare Pharmaceuticals, Bracco Group, E-Z-EM Inc., Covidien, Cytogen Corp., Daiichi Sankyo Company Limited, Eisai Co., Ltd, EPIX Pharmaceutical Inc., Guerbet Group, and Lantheus Medical Imaging. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• A. Contrast Media
  • X-Ray Contrast Media
  • Magnetic Resonance Imaging (MRI) Contrast Media
  • Ultrasound Contrast Media
• B. Diagnostic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. Industry Overview

• A Quick Primer On Imaging Agents
• Growth Drivers
• Growth Inhibitors
• Changing Dynamics of Imaging Agents
• Imaging Agents: Significant Growth Ahead
• Table 1: Worldwide Imaging Agents Market (2003): Percentage Breakdown of Value Sales for Leading Imaging Agents-Omnipaque, Cardiolite, Magnevist, Iopamiron, Ultravist, Myoview, Visipaque, Omniscan, FDG and Others (includes corresponding Graph/Chart)
• Rise of Non-Ionizing Imaging Techniques
• Table 2: Medical Diagnostic Procedures Conducted Worldwide for the Year 2003: Breakdown by Imaging Modality Type - X-ray/CT, MRI, Ultrasound and Radiopharmaceuticals (In Millions) (includes corresponding Graph/Chart)
• Fusion Imaging Modalities: Greater Clinical Benefits
• Radiopharmaceuticals-An Exotic Tool
• Nanomaterials Taking the Center Stage
• Gadolinium Coated Nanoparticles- A Promising Imaging Agent
• A Peek Into the Pricing Dynamics
• A Synoptic Overview
• Pros & Cons
• Positive Factors Driving Prices
• Negative Factors Bearing Down on Prices
• Reimbursements
• "Under the Umbrella"
• Europe
• United States

2. Market Trends & Issues

• Falling Prices Turn On the Heat
• X-Ray Contrast Media: Declining Sector
• MRI Contrast Media: Playing at Center Court
• Impact Wielded by Ballooning MRI Practices
• Ultrasound Contrast Media: A Rising Star in the Quadrant
• Fledging Market Battles Teething Challenges
• PET: A Prime Growth Driver for Radiopharmaceuticals
• Nuclear Medicine: A Potential Growth Avenue for Radiopharmaceuticals
• Select Cardiology and Oncology Radiopharmaceuticals

3. Competition

• Market Structure
• Key Market Metrics
• Big Guns in the Emerging MRI Market
• Bayer Schering Pharma AG: A Pioneering Developer of MRI Contrast Agents
• Competitive Scenario - A Recent Past Perspective
• Table 3: Worldwide Imaging Agents Market (2004): Percentage Breakdown of Value Sales for Leading Players- GE Healthcare, Bracco, Tyco Healthcare/Mallinckrodt, Schering, BMS and Others (includes corresponding Graph/Chart)
• Table 4: X-ray Medical Diagnostics Market Worldwide: Percentage Market Share of Leading Players for the Years 2002, 2003, and 2004 - Amersham, Bracco, Tyco/ Mallinckrodt, Inc, Schering, Guerbet and Others (Revenue Share) (includes corresponding Graph/Chart)
• Table 5: MRI Diagnostics Market Worldwide: Percentage Share of Leading Players for the Years 2003 and 2004 - Schering, Amersham, Bracco, and Others (Revenue Share) (includes corresponding Graph/Chart)
• Table 6: Radiopharmaceutical Medical Diagnostics Market Worldwide: Percentage Market Share of Leading Players for the Years 2003 and 2004 - Amersham, Bristol-Myers Squibb, Tyco/ Mallinckrodt, Inc and Others (Revenue Share) (includes corresponding Graph/Chart)

4. Technology Breakthroughs

• Molecular Imaging Agents: The Outer Limits
• On Cards: Hyperpolarized Gases as Contrast Agents
• Imaging Agents Make a Welcome Impact in the Field of Alzheimer' s Disease
• Technetium-99m: A Breakthrough Contrast Agent for CNS Imaging
• A New Imaging Agent for Radiopharmaceutical Scans
• Multi-Modal Image Registration: Combating Contrast Medium Inconsistencies
• Saline Flushes To Help Ensure Accurate Delivery of Contrast Agents

5. Product Overview

• Contrast Agents
• Contrast Media: How Do They Function?
• Where Are They Used...?
• Evolution of Contrast Media: A Profile
• Bismuth Nitrate: Beginning of Contrast Agents
• Imaging Agents: Significant Developments in the Last Fifty Years
• Schering Develops First Intravenous Contrast Agent
• MRI: Creating a New Era for Contrast Agents
• A Peek into the Finer Points of Differences Among Contrast Media
• Viscosity
• Osmolality
• Chemotoxicity
• Second Generation Non-Ionic Contrast Agents: An Introduction
• Choice of the Contrast Medium: A Weighty Decision
• Factors affecting choice of Imaging Agents
• Taxonomy
• Types of Contrast Media
• X-Ray Contrast Medium
• First Generation High Osmolar Contrast Media
• Second Generation Low Osmolar Contrast Media or LOCM
• Table 7: Comparative Analysis of Structure of Non-ionic and ionic X-ray Contrast Media
• MRI Contrast Medium
• Role of Contrast Enhancement in MR Angiography (MRA)
• MRI Contrast Agents for the Liver
• Paramagnetic extracellular contrast agents
• Hepatobiliary Gadolinium Chelates
• Superparamagnetic Iron Oxide Particles
• Ultrasound Contrast Medium
• Ultrasonographic Contrast Media: What Are They?
• Ultrasound Contrast Enhancement in Cardiology
• Functionalities of Vascular Ultrasound Contrast Agents
• Diagnostic Radiopharmaceuticals
• Key Radioactive Isotopes used as Diagnostic Radiopharmaceuticals
• A Delineate of Diagnostic Radiopharmaceuticals
• Diagnostic Radiopharmaceuticals: A Technical Run-Through
• Applications

6. A Segmental Review

• Contrast Media
• Popular Brands of Contrast Agents Available Worldwide
• A Peek into Select Imaging Agents Under Clinical Trials Worldwide
• X-ray Contrast Media
• Market Scenario
• MRI Contrast Media
• Market Scenario
• Ultrasound Contrast Media
• Market Overview
• Competitive Scenario
• Diagnostic Radiopharmaceuticals
• Market Overview
• Immunoconjugates
• Market Overview
• Competitive Scenario

7. Technology Dynamics

• Proprietary Technologies Making Significant In-Roads
• Advanced Magnetics' Proprietary Colloidal Superparamagnetic Particle Technology
• Enzon' s Single Chain Antigen-Binding Technology
• Immunomedics' Antibody Technology
• First Generation
• Second Generation
• Third Generation
• NeoRx' s "Painting the Target" Technology
• Stage - I
• Stage - II
• Stage - III
• Gas Encapsulation Technology for Ultrasound Contrast Media
• Pharmacyclics' Texaphyrin Technology
• Regulatory Bodies
• Ultrasound Contrast Agents Are Drugs, Not Devices - Rules US FDA
• Entry Barriers
• Research Driven Markets
• Highly Competitive Market
• Economies of Scale
• Substitutes in Agents Manufacturing
• New X-ray Diagnostic Agents
• Amide-based Macrocyclic Ligands - Potential MRI Agents
• Gadolinium (III) Complexes - Potential MRI Contrast Agents
• Metal-Containing Compounds Act As Potential Contrast Agents
• Therapeutic Applications
• Diagnostic Applications
• Magnetic Gels as Potential MRI Contrast Agents
• PFCs as Diagnostic Contrast Agents

8. Product Launches

• Bayer to Unleash Radiology Management System
• Bayer to Unveil Pre-Filled Contrast-Medium Cartridges for MRI
• Insight Agents to Launch Generic Contrast Media Solutions In Europe
• Researchers Develop First Biocompatible MRI Contrast Agent
• Signalomics and Invitrogen Collaborate to Develop Nanocrystal Reagents
• Schering AG Collaborates with Stanford University to Develop Molecular Imaging Agent
• Schering and Avid to Develop Diagnostic Imaging Agents
• US National Institutes of Health Develops two PET Imaging Agents
• Bracco Diagnostics Canada Introduces MRI Contrast Agent MultiHance
• JBCPL Launches Magnilek Contrast Agent
• Mallinckrodt Launches NeutroSpec™
• Schering AG' s Primovist™ Approved in Sweden
• Isovue - A Non-ionic Monomeric X-Ray Contrast Agent from Bracco Diagnostics
• Schering Strengthens Position with MS-325
• Berlex Launches MRI Contrast Agent
• Amersham Health Introduces Omnipaque
• Boston Scientific Corp Launches Galaxy System
• Syncor International Launches F-18 FDG

9. Recent Industry Activity

• Bristol-Myers Squibb Medical Imaging Adopts New Identity, Lantheus Medical Imaging
• Cytogen Corporation to Merge Business with EUSA Pharma Inc
• Bracco Group Acquires E-Z-EM
• EPIX Pharmaceuticals to Resubmit New Drug Application (NDA) for Vasovist
• Bayer Schering, FutureChem Ink Licensing Deal
• NuView Radio Pharmaceuticals Inks Agreement for Non- Invasive Imaging Agent
• Advanced Magnetics Inc Changes Name to AMAG Pharmaceuticals
• Bracco Diagnostics Inks Agreement with HealthTrust Purchasing Group
• Bracco Diagnostics Offers MRI Products to HealthTrust Purchasing Group
• Bayer HealthCare Offers MRI Contrast Agent to HealthTrust
• Bayer HealthCare Extends Contract with Premier
• Bayer HealthCare Sets Off US Operations
• Tyco Healthcare Renamed to Covidien Ltd
• Covidien Offers Imaging Solutions to MedAssets Supply Chain Systems
• Siemens, M.D. Anderson Cancer Center Set up Research Centre
• Bayer, Berlex Merge Operations
• AION Diagnostics Forays Pre-Clinical Imaging Agent Market
• ART Acquires Alerion Biomedical
• EPIX to Merge with Predix
• Fujifilm Acquires Stake in Daiichi Radioisotope Laboratories
• Bracco Diagnostics Inks Agreement with Amerinet Vasovist receives Green Signal in Australia
• AION Diagnostics Develops BioSilicon TM
• Sonazoid Receives Import Approval
• Schering AG Divests Radiopharmaceutical Business to Ion Beam Applications and Institut National des Radioelements
• Vasovist Receives European Approval
• Albany Molecular Research Renews Supply Agreement with GE Healthcare
• QuantRx Biomedical Corp. Acquires Stake in FluoroPharma
• Palatin Technologies Withdraws NeutroSpec Imaging Agent
• Diosynth Bags Contract to Produce Imaging Agent
• GE Healthcare Signs Marketing Agreement with PhotoCure
• DRAXIMAGE Receives the Green Signal in Europe
• Daiichi and Sankyo Sign a Merger Deal
• Bristol Myers and Imcor Pharmaceutical Forge Cross- Licensing Agreement
• Kereos and Dow to Develop Unique Targeted Imaging Agents
• Bristol-Myers and Kereos to Collaborate on Molecular Imaging Agents
• GE Acquires Amersham PLC
• Photogen Technologies Acquires Imagent®
• Dow and Kereos Collaborate
• IBC Pharmaceuticals and Schering AG Collaborate on Cancer Research
• Schering Purchases CIS Bio International
• Imaging Diagnostic Systems to Collaborate with Schering
• Mallinckrodt Signs Distribution Agreement with Proxima Therapeutics
• Immunomedics Signs Marketing Agreement with Teva-Tuteur
• DRAXIS Increases BrachySeed Production
• DRAXIMAGE Obtains FDA Approval for Manufacturing Lyophilized Products
• Nycomed Amersham Acquires Bruker' s TOMOJET
• DuPont Acquires Caribbean-PharmaLogic Radiopharmacies
• Bristol-Myers Squibb Company Acquires DuPont Pharmaceuticals
• Alliance Pharmaceutical Completes Acquisition of Molecular Biosystems
• GE Medical Acquires Coincidence Technologies
• Tyco International Acquires Mallinckrodt
• Zydus Cadila Acquires 27.72 % Stake in German Remedies
• Schering Acquires Manufacturing Rights of MS-325 from EPIX Medical
• Zydus Cadila Acquires Five Brands from Asta Medica
• AxCell BioSciences Forms Joint Venture with Institute for Systems Biology
• Syncor Signs Purchasing Agreements with HSCA
• Syncor and InSource Health Services Sign Agreement
• DRAXIS Signs Agreement with BTG for INFECTON
• Peregrine Pharmaceuticals and Paul Scherrer Institute Expand R&D Agreement
• Syncor and Broadlane Ink Agreement
• Syncor and Catholic Healthcare West Extend Agreement
• MedImmune and Targesome Sign R&D Agreement
• Vital Images Inks an Agreement with E-Z-EM Inc
• TriPath Imaging and MDS Ink Agreement
• North American Scientific Forges Strategic Relationship with Certus International
• Mediaworks Launches RadiologyWeb
• Nycomed Amersham Extends Supply Contract with Novation
• Advanced Magnetics Receives Approval for Feridex
• Targesome Receives NCI Support for Developing Novel Diagnostic Imaging Agents
• Bracco Acquires Product Lines and Intellectual Property of Resolution Pharmaceuticals
• Guerbet Acquires Oxilan, an X-Ray Contrast Agent from Cook Imaging
• Nycomed Amersham Imaging Associates with Global Healthcare Exchange
• Nycomed Amersham and D-Pharm Ally to Develop New Imaging Agents
• Bracco Group Forges Strategic Alliance with Dyax Corp
• DRAXIS Signs Agreement with Cytogen Corp
• CV Therapeutics and Fujisawa Healthcare Sign Collaboration Agreement
• Comprehensive Medical Imaging Signs Agreement with US Diagnostic
• Syncor International and GE Medical Systems Sign Strategic Agreement
• Guilford Pharmaceuticals Licenses Dopascan to MAP Medical Technologies
• Cytogen and Advanced Magnetics Sign Agreements
• Amersham Sells Nycomed Pharma Subsidiary
• Amersham Renames its Businesses
• Nycomed Amersham Obtains Approval from FDA for MYOVIEW
• Schering Obtains Approval for Cancer Imaging Agent
• Datscan Receives European Union Marketing Authorization

10. Focus on Select Players

• AMAG Pharmaceuticals Inc (USA)
• Amersham Plc (UK)
• Bayer Schering Pharma AG (Germany)
• Bayer HealthCare Pharmaceuticals (US)
• Bracco Group (Italy)
• E-Z-EM Inc. (USA)
• Covidien (USA)
• Cytogen Corp. (USA)
• Daiichi Sankyo Company Limited (Japan)
• Eisai Co., Ltd (Japan)
• EPIX Pharmaceutical Inc. (USA)
• Guerbet Group (France)
• Lantheus Medical Imaging (USA)

11. Global Market Perspective

• Table 8: World Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 9: World Long-term Projections for Imaging Agents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 10: World 10-Year Perspective for Imaging Agents by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 11: World Recent Past, Current & Future Analysis for Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 12: World Long-term Projections for Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 13: World 10-Year Perspective for Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 14: World Recent Past, Current & Future Analysis for Contrast Media by Product Segment - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 15: World Long-term Projections for Contrast Media by Product Segment - X-Ray, MRI and Ultrasound Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 16: World 10-Year Perspective for Contrast Media by Product Segment - Percentage Breakdown of Dollar Sales for X-Ray, MRI and Ultrasound Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 17: World Recent Past, Current & Future Analysis for X-Ray Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 18: World Long-term Projections for X-Ray Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 19: World 10-Year Perspective for X-Ray Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 20: World Recent Past, Current & Future Analysis for MRI Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 21: World Long-term Projections for MRI Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 22: World 10-Year Perspective for MRI Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 23: World Recent Past, Current & Future Analysis for Ultrasound Contrast Media by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 24: World Long-term Projections for Ultrasound Contrast Media by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 25: World 10-Year Perspective for Ultrasound Contrast Media by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
• Table 26: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 27: World Long-term Projections for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 28: World 10-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region- Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Middle East and Latin America Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
  • Outlook
  • Growth Stimulants
  • Medical Imaging: Changing the Healthcare Landscape
  • Dynamics of Pricing
  • Table 29: Hospital Purchases by GPOs in the United States - Percentage Breakdown by Type for the Year 2002 (includes corresponding Graph/Chart)
  • Reimbursements Issues
  • Medicare
  • Magnetic Resonance Imaging
  • Table 30: Medicare Reimbursements for Brain MRI Procedures for the Year 2006
  • Table 31: Medicare Reimbursements for Breast MRI Procedures for the Year 2006
  • Regulatory Environment
  • Provisions Regarding Off-Label Usage of Contrast Media
  • Contrast Media
  • X-ray Contrast Media
  • MRI Contrast Media
  • Market Scenario
  • Managed Care Vs MRI Technology Diffusion
  • Ultrasound Contrast Media Market
  • Diagnostic Radiopharmaceuticals
  • Market Scenario
  • Availability of Isotopes: A Tough Challenge
  • Select Players
  • Strategic Corporate Developments
  • Product Launches
• B. Market Analytics
  • Table 32: US Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 33: US Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 34: US Historic Review for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 1999 (includes corresponding Graph/Chart)
  • Table 35: US 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

2. Canada

• A. Market Analysis
  • Outlook
  • Diagnostic Equipment Market
  • LOCM Products Approved in Canada
  • Select Player
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 36: Canadian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 37: Canadian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 38: Canadian 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

3. Japan

• A. Market Analysis
  • Outlook
  • Reimbursement Issues
  • Select Players
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 39: Japanese Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 40: Japanese Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 41: Japanese 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4. Europe

• A. Market Analysis
  • Outlook
  • Trends
  • Reimbursement
  • Distribution Structure
  • Direct Sales
  • License Agreements
  • Distribution Agreements
  • A Price Sensitive Market
  • Table 42: European Contrast Media Market (2005): Average Cost of Contrast Media Per Imaging Procedure
  • Table 43: Product Price of Select Contrast Agents in Europe by Company
  • Macro Market Environment
  • Germany
  • France
  • United Kingdom
  • Spain & Italy
  • Scandinavia
  • Strategic Corporate Developments
  • Product Launch
• B. Market Analytics
  • Table 44: European Recent Past, Current & Future Analysis for Imaging Agents by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 45: European Long-term Projections for Imaging Agents by Geographic Region - France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 46: European 10-Year Perspective for Imaging Agents by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, UK, Italy, Spain, Russia and Rest of Europe Markets for Years 2003, 2008 & 2012 (includes corresponding Graph/Chart)
  • Table 47: European Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 48: European Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 49: European 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4a. France

• A. Market Analysis
  • Outlook
  • Growth Stimulants
  • Contrast Media
  • Major Player
  • Strategic Corporate Developments in the Recent Past
• B. Market Analytics
  • Table 50: French Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radio-pharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 51: French Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 52: French 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4b. Germany

• A. Market Analysis
  • Outlook
  • Major Player
  • Strategic Corporate Developments
  • Product Launches
• B. Market Analytics
  • Table 53: German Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 54: German Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 55: German 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4c. The United Kingdom

• A. Market Analysis
  • Outlook
  • Major Player
  • Strategic Corporate Developments in the Recent Past
• B. Market Analytics
  • Table 56: UK Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 57: UK Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 58: UK 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4d. Italy

• A. Market Analysis
  • Outlook
  • Major Player
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 59: Italian Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 60: Italian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 61: Italian 10-Year Perspective for Imaging Agents by Product Segment-Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4e. Spain

• Market Analysis
• Table 62: Spanish Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radio- pharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 63: Spanish Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 64: Spanish 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4f. Russia

• Market Analysis
• Table 65: Russian Recent Past, Current & Future Analysis for Imaging Agents by product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 66: Russian Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 67: Russian 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

4g. Rest of Europe

• A. Market Analysis
  • Outlook
  • Strategic Corporate Developments
• B. Market Analytics
  • Table 68: Rest of Europe Recent Past, Current & Future Analysis for Imaging Agents by Product Segment-Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 69: Rest of Europe Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 70: Rest of Europe 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

5. Asia-Pacific

• A. Market Analysis
  • Outlook
  • PET Imaging-An Overview
  • ANSTO: Leading the Radiopharmaceuticals Market
  • Strategic Corporate Developments
  • Product Launch
• B. Market Analytics
  • Table 71: Asia-Pacific Recent Past, Current & Future Analysis for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
  • Table 72: Asia-Pacific Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
  • Table 73: Asia-Pacific 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

6. The Middle East

• Market Analysis
• Table 74: Middle East Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 75: Middle East Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 76: Middle East 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

7. Latin America

• Market Analysis
• Table 77: Latin American Recent Past, Current & Future Analysis for Imaging Agents by Product Segment- Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 78: Latin America Long-term Projections for Imaging Agents by Product Segment - Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
• Table 79: Latin American 10-Year Perspective for Imaging Agents by Product Segment- Percentage Breakdown of Dollar Sales for Contrast Media (X-ray, MRI and Ultrasound) and Diagnostic Radiopharmaceuticals Markets for 2003, 2008 & 2012 (includes corresponding Graph/Chart)

COMPETITIVE LANDSCAPE